Gastrointestinal Radiation Treatment Volume After Practice-Changing De-escalation Trials and Implications for Resident Disease-Site Case Availability
Advances in Radiation Oncology · 2026-10 · 102246
DOI: 10.1016/j.adro.2026.102246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Radiation Oncology, 2026-10. Verfasst von Ted K. Yanagihara und 1 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
PROSPECT (rectal) and ESOPEC (esophageal/gastroesophageal-junction [GEJ]) support omission of neoadjuvant radiation therapy (RT) for selected patients, raising concern that fewer cases will be available to residents. We describe gastrointestinal (GI) RT volume over a decade and estimate the probability that a rotation block contains zero treatment starts for a given disease site by rotation length and era. Methods and Materials We retrospectively identified GI RT at a tertiary medical center over 10 years by disease sub-site. Monthly treatment counts and pre- versus post-trial mean monthly treatments were reported with 95% confidence intervals (CI) and compared with two-sample t-tests. Pre-existing trends were tested by linear regression. We estimated the probability of zero treatment starts within one-, two-, and three-month rotation blocks over the full window and within each era, and compared consult trends between Medical Center and its Regional Sites.
Results
We identified 931 GI treatment starts (liver 294, rectal 234, esophageal/GEJ 183, pancreatic 125, and anal 95). Mean monthly treatments were modestly lower after the trials for rectal (2.12 to 1.60, difference −0.52 per month [95% CI −1.08 to 0.05] and esophageal/GEJ 1.57 to 1.35, −0.22 [−0.87 to 0.44]), higher for liver (2.35 to 2.77, +0.43 [−0.23 to 1.08]) and pancreatic (0.92 to 1.37, +0.45 [0.03 to 0.88]), and stable for anal (0.81 to 0.77, −0.04 [−0.38 to 0.30]). No site showed a pre-existing trend. The probability of zero treatment starts on a two-month rotation was rectal (2%), esophageal/GEJ (8%), liver (1%), pancreatic (13%), and anal (22%), falling to 1%, 3%, 0%, 9%, and 11% for three-month blocks. The ranking of sites was unchanged within the pre- and post-trial eras. Consult volume declined gradually and in parallel between the Medical Center and Regional Sites.
Conclusions
There has been no sudden collapse in rectal and esophageal RT volumes following de-escalation trials. Declines at the trial-affected sites were modest and not statistically significant, whereas the risk of zero case availability on short rotations is substantial for inherently low-volume sites. Programs can apply this approach to their own data to set rotation length and scheduling to meet clinical training needs.
Zitieren
APA
Yanagihara, T. K., & Casey, D. (2026). Gastrointestinal Radiation Treatment Volume After Practice-Changing De-escalation Trials and Implications for Resident Disease-Site Case Availability. Advances in Radiation Oncology, 102246. https://doi.org/10.1016/j.adro.2026.102246
Vancouver
Yanagihara TK, Casey D. Gastrointestinal Radiation Treatment Volume After Practice-Changing De-escalation Trials and Implications for Resident Disease-Site Case Availability. Advances in Radiation Oncology. 2026:102246. doi:10.1016/j.adro.2026.102246
BibTeX
@article{Yanagihara2026,
author = {Yanagihara, Ted K. and Casey, Dana},
title = {Gastrointestinal Radiation Treatment Volume After Practice-Changing De-escalation Trials and Implications for Resident Disease-Site Case Availability},
journal = {Advances in Radiation Oncology},
year = {2026},
pages = {102246},
doi = {10.1016/j.adro.2026.102246}
}
EUVIMED